6541.TW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 23:40):

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States...

Stats
Today's Volume	120 390
Average Volume	327 547
Market Cap	7.53B
EPS	TWD0 ( 2024-03-14 )
Next earnings date	( TWD0 ) 2024-05-13
Last Dividend	TWD0 ( N/A )
Next Dividend	TWD0 ( N/A )
P/E	-2.90
ATR14	TWD0.0730 (0.15%)

Volume Correlation

Long: -0.16 (neutral)

Short: 0.56 (weak)

Signal:(59.533) Neutral

Tanvex BioPharma, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Tanvex BioPharma, Inc. Correlation - Currency/Commodity

-0.54
( weak negative )

0.00
( neutral )

-0.49
( neutral )

0.36
( neutral )

-0.33
( neutral )

Tanvex BioPharma, Inc. Financials

Annual	2023
Revenue:	TWD61.41M
Gross Profit:	TWD-265.13M (-431.73 %)
EPS:	TWD-16.42

Q4	2023
Revenue:	TWD9.09M
Gross Profit:	TWD-79.89M (-879.18 %)
EPS:	TWD-3.83

Q3	2023
Revenue:	TWD5.11M
Gross Profit:	TWD4.12M (80.61 %)
EPS:	TWD-3.74

Q2	2023
Revenue:	TWD17.08M
Gross Profit:	TWD11.04M (64.65 %)
EPS:	TWD-3.85

Financial Reports:

No articles found.

Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.